Pharma BD Deal Intelligence

AstraZeneca PLC / Takeda Pharmaceutical Company Limited (core respiratory business)

2015 · Asset Purchase · $575M · Complete

Announcement Sentiment

Strongly positive

AstraZeneca acquired Takeda's core respiratory business including expanded global rights to roflumilast (Daliresp/Daxas), the only approved oral PDE4 inhibitor for COPD, for $575M. Closed 2016.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Dec 16, 2015
Closed Jun 02, 2016
Deal value $575M
Deal type Asset Purchase
Therapeutic area Chronic obstructive pulmonary disease (COPD)
Indications Chronic obstructive pulmonary disease (COPD)
Key assets Roflumilast (Daliresp / Daxas)
Mechanism Oral phosphodiesterase 4 (PDE4) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals